Notícias e Atividades da Otsuka Holdings

Otsuka Holdings é uma das ...

• Forbes Global 2000 (#654);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Otsuka Holdings é uma empresa listada sob o símbolo 4578 (JP).

Otsuka Holdings tem presença direta em 11 países.

Otsuka Holdings possui 23 subsidiárias incluindo Araris Biotech, Cambridge Isotope Laboratories e Interpharma.

Eles estão dentro:

• Farmacêutica46%
• Equipamentos Médicos29%
• Outro25%

Veja o organograma con seus 263 executivos principais

Biografias mais buscadas da Otsuka Holdings

• Makoto Inoue, President and Representative Director, Chief Executi...
• Yukio Matsutani, Independent Director
• Jiro Seguchi, Outside Director and Board Member

Criar um alerta
para seguir os movimentos de executivos da Otsuka Holdings.

Otsuka Holdings possui 3.493 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Kaiser Permanente (Estados Unidos) e HCA (Estados Unidos).

Popular M&A news in Saúde

• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Freeman Health System adquiriu Northwest Health (publicado em 2 de junho de 2026).
• Garner Health acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 29 de maio de 2026).

Outros contatos sugeridos na indústria do Saúde

• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board da Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer da Royalty Pharma

Saiba mais sobre a indústria do Saúde

Últimos comunicados de imprensa de Otsuka Holdings

• Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy SupplementsFacilitating the Research and Development of Gummy Products｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in VietnamSupporting Health and Meeting Growing Demand｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human PotentialProvide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle｜New
• Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Is Now on Sale - Insurance coverage begins on March 1, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET BottlesPartnering with Its Factory to Promote a "Local Production and Local Recycling" Initiative for PET Bottles｜News Releases | Otsuka Pharmaceutical Co.,
• Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• View more press releases Close

Redes sociais sobre Otsuka Holdings

• Otsuka Holdings na Wikipedia, Google News e Yahoo Finance
• Otsuka Holdings na LinkedIn, X (Twitter) e YouTube